Corregene Biotechnology Co., Ltd

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1
KRAS G12V presented on HLA-A*11:01Cell therapy
Non-Small Cell Lung CancerColorectal CancerPancreatic Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.